Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

178 results about "Ischemic brain injury" patented technology

Specific conditions associated with an ischemic brain injury are a stroke or a transient ischemic attack, often called a TIA, and cerebral palsy. Ischemic brain injuries result in permanent damage to part of the brain lacking blood flow, and may affect physical functioning, thinking and behavior.

Treatment of ischemic brain injuries with brain targeted anti oxidant compounds

A method of reducing oxidative stress in the brain of an organism having a blood brain barrier and suffering an ischemic brain injury, the method comprising the step of administering a compound to the organism, the compound having (a) a combination of molecular weight and membrane miscibility properties for permitting the compound to cross the blood brain barrier of the organism; (b) a readily oxidizable chemical group for exerting antioxidation properties; and (c) a chemical make-up for permitting the compound or its intracellular derivative to accumulate within the cytoplasm of cells.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +1

Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells

A method for treating or preventing an ischemic brain injury or neurological damage due to ischemia in a subject includes transplanting a therapeutically effective amount of human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the ischemic areas of the brain injury or the neurological damage of the subject. Recovery from neurological behavior deficits also is improved according by the method.
Owner:FU YU SHOW +1

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.
Owner:SHANGHAI HANSOH BIOMEDICAL +1

Endothelial-monocyte activating polypeptide II, a biomarker for use in diagnosis and treatment of brain injury

A diagnostic tool and method of diagnosing brain injury and brain injury type (traumatic vs. ischemic) by detecting the level of expression of endothelial monocyte-activating polypeptide II (EMAP-II) and comparing to a control. An increase of EMAP-II indicates the presence of traumatic brain injury and a decrease of EMAP-II indicates the presence of ischemic brain injury. Detection of EMAP-II can be done in brain tissue, biofluids such as cerebrospinal fluid or blood (including plasma and serum)
Owner:UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SEC OF THE ARMY +1

Medicinal compositions improving brain function and method for improving brain function

An alkyl ether derivative represented by the formula: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.
Owner:TOYAMA CHEM CO LTD

High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and / or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.
Owner:UNIVERSITY OF COPENHAGEN

Medicinal compositions improving brain function and method for improving brain function

An alkyl ether derivative represented by the formula:wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.
Owner:TOYAMA CHEM CO LTD

Target spot and medicine for treating cerebral injury

The invention relates to a target spot and a medicine for treating cerebral injury, in particular to a material used for maintaining TRPC6 (Transient Receptor Potential-canonical Channel) level to prevent or treat hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration, and application thereof in preparation of a medicine or medicine composition for preventing or treating the hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration. The invention also relates to a method for screening materials capable of being used for treating or preventing injury caused by ischemia.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI

Treatment of ischemic brain injuries with brain targeted antioxidant compounds

A method of reducing oxidative stress in the brain of an organism having a blood brain barrier and suffering an ischemic brain injury, the method comprising the step of administering a compound to the organism, the compound having (a) a combination of molecular weight and membrane miscibility properties for permitting the compound to cross the blood brain barrier of the organism; (b) a readily oxidizable chemical group for exerting antioxidation properties; and (c) a chemical make-up for permitting the compound or its intracellular derivative to accumulate within the cytoplasm of cells.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +2

Achyranthes bidentata polypeptide, preparing process and uses

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.
Owner:NANTONG UNIVERSITY

Medicament for preventing and treating ischemic brain injury, and preparation method thereof

The invention relates to the field of Chinese medicaments, in particular to a Chinese medicinal composition for preventing and treating ischemic brain injury, and a preparation method thereof. The Chinese medicinal composition for preventing and treating ischemic brain injury is an orally taken preparation prepared from extracts of raw astragalus roots, panax notoginseng, kudzuvine roots, baikal skullcap roots and gardenia serving as main active components, as well as pharmaceutical auxiliary materials. The preparation has obvious therapeutic effects on cerebral infarction convalescent symptoms of which the clinical manifestations are eye-mouth distortion, glossolalia, slobbering or hemiplegia, dark red tongue or yellow greasy tongue coating, weak or uneven pulse and the like.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Saflor yellow pigment rich in saflor yellow pigment B, its preparation method and use

The present invention relates to a carthamus yellow richly containing carthamus yellow B, in which the carthamus yellow B content is greater than or equal to 80% and less than 100%, the optimized content is greater than or equal to 90% or less than 100%. Said invention also relates to its preparation method and medicine composition containing said carthamus yellow. Said invention also provides its application in preparation of medicine for preventing and curing ischemic brain injury.
Owner:SHANDONG GREENERY NATURAL MEDICINE RES & DEV

Hyperforin analogs, methods of synthesis, and uses thereof

The present invention provides a novel 11-step enantioselective approach to the natural product hyperforin, which enables access to a wide variety of hyperforin analogs. The present invention also provides pharmaceutical compositions comprising inventive hyperforin analogs. Hyperforin analogs synthesized using the present synthetic method are envisionsed useful in the treatment of various conditions, including, but not limited to, depression and conditions characterized by depression, inflammatory skin conditions, diabetes, asthma, chronic obstructive pulmonary disease (COPD), kidney disorders, and ischemic brain damage.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

PSD-95 inhibitor

The invention relates to the field of medicine synthesis, and discloses a PSD-95 inhibitor. The PSD-95 inhibitor disclosed by the invention is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is used for preparing neuroprotective drugs after ischemic brain injury.
Owner:CHENGDU AODA BIOTECHNOLOGY CO LTD

Small peptide TAT-AVPY for treating ischemic brain damage, and application thereof

The invention discloses a small peptide TAT-AVPY for treating ischemic brain damage, and an application thereof. The complete sequence of the small peptide TAT-AVPY is H-YGRKKRRQRRR-AVPY-OH, represented by SEQ ID NO:1. With the small peptide TAT-AVPY provided by the invention, the binding of XIAP and proaspase-9 (Casp 9) can be reduced; nitrosylation of XIAP and proaspase-9 (Casp 9) can be alleviated; and proaspase-9 activation can be alleviated. Therefore, cell apoptosis induced by cerebral ischemia can be alleviated. Also, TAT can directly bring fused small peptide into cells, such that a problem of the approach for the drug to enter cells is solved, and medication is convenient. The small peptide TAT-AVPY has no immunogenicity, and does not cause an immune response of a body. Therefore, side effects are reduced, and the effectiveness of secondary medication or more is ensured.
Owner:许铁

3,4-diphenyl-4H-1,2,4-triazole derivative as well as preparation method and application thereof

The invention discloses a 3,4-diphenyl-4H-1,2,4-triazole derivative as well as a preparation method and application thereof. Specifically, the invention relates to a 3,4-diphenyl-4H-1,2,4-triazole derivative of a structure represented by the formula (I), and a stereisomer or pharmaceutically acceptable salt of the derivative, wherein the definition of each substituent in the formula (I) is the same as that in a specification. Compounds of novel structures have the activity of inhibiting heat shock proteins HSP90, can be used for treating cancers, neurodegenerative diseases, inflammatory diseases, autoimmune diseases and ischemic brain injuries, and has wide application prospect.
Owner:SHANGHAI HANSOH BIOMEDICAL +1

Use of kauranes compounds in the manufacture of medicament

ActiveUS20100179097A1Decreased cardiac outputEnhancing cardiac contractile functionBiocideElcosanoid active ingredientsCoronary heart diseaseAcyl group
This invention relates to the use of kauranes compounds having the structure of formula (I) in the manufacture of a medicament for treating and preventing the diseases such as coronary heart disease, cerebral apoplexy, cerebral ischemia and rhythm disturbance etc. The present compounds also have obvious protective effect against cerebral infarction and cerebral injure from ischemia, in which: R1 is H, hydroxy or alkoxy; R2 is carboxy, carboxylate group, acyl halide, aldehyde group, hydroxymethyl, ester group which can be hydrolyzed to carboxy, amide, acyl or ether group; R3, R4, R5, R6, R8 each independently are H, hydroxy, hydroxymethyl, ester group which can be hydrolyzed to hydroxymethyl, or alkoxymethyl; R7 is methyl, hydroxymethyl, ester group which can be hydrolyzed to hydroxymethyl, or alkoxymethyl; R9 is methylene or oxygen atom.
Owner:TAN KS

Application of (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone in preparing medicine for treating cerebrovascular diseases

The invention discloses application of (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone in preparing a medicine for treating cerebrovascular diseases. The related research indicates that the compound has an obvious cranial nerve protection effect, obviously reduces the focal cerebral ischemia rat cerebral infarction volume and remarkably improves the neurologic symptom. The (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone is used for preventing or treating the diseases such as ischemic brain injury, cerebral hemorrhage, cerebral thrombosis, cerebral embolism, cerebral infarction, cerebral apoplexy, lacunar infarction, transient ischemic attack, cerebral arteriosclerosis, diabetic cerebrovascular complications and the like.
Owner:SUZHOU UNIV

Application of genipin in prevention or treatment of ischemic brain injury

The invention relates to application of genipin in prevention or treatment of ischemic brain injury. Brain injury is particularly related to injury of microglial cells or human umbilical vein endothelial cells. The invention further relates to a medicine composition containing genipin for preventing or treating ischemic brain injury.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI

Application of BK channel opener in establishing vascular smooth muscle cell calcification model

InactiveCN107303296AOrganic active ingredientsRespiratory disorderDiseaseVascular smooth muscle relaxation
The invention belongs to the field of bio-pharmaceuticals, relates to a novel application of a novel inhibitor large-conductance calcium-activated potassium channel (also called a BK channel) opener NS1619 influencing a process of establishing a vascular smooth muscle cell calcification model, specifically relates to an application of the NS1619 used for establishing the vascular smooth muscle cell calcification model, and in particular relates to a novel application of the NS1619 used for preparing drugs for inhibiting vascular smooth muscle cell calcification. Cell experiment results prove that the NS1619 has effects of inhibiting vascular smooth muscle cell calcification, including an effect of inhibiting Ca<2+> deposition in the calcification process, an effect of inhibiting molecular expression of a calcification marker molecule and an effect of inhibiting formation of calcium nodules. The NS1619 can be further used for preparing drugs for treating diseases related to vascular sclerosis and smooth muscle contraction or relaxation dysfunction, including treatment of atherosclerosis, asthma, cerebral ischemic injury, uroschesis and other smooth muscle dysfunction related diseases.
Owner:FUDAN UNIV

Application of nicotinamide phosphoribosyltransferase in preparation of neuroprotective drugs

InactiveCN103961691AStimulate or enhance regenerationPromote repairNervous disorderPeptide/protein ingredientsBrain HypoxiaRisk stroke
Belonging to the pharmaceutical field, the invention relates to application of nicotinamide phosphoribosyltransferase (NAMPT) in preparation of neuroprotective and rehabilitation drugs. Experiments of the invention show that NAMPT recombinant protein can penetrate the blood-brain barrier to significantly reduce the volume of ischemic brain injury and alleviate white matter injury after ischemic brain injury; the NAMPT recombinant protein can significantly improve long-term behaviors after ischemic brain injury; the NAMPT recombinant protein can raise revascularization related factors to enhance revascularization after brain hypoxia and neuron regeneration after brain hypoxia, and promote post-injury neurologic function reestablishment; and by mediating oligodendrocyte regeneration and alleviating the demyelination effect of local lysolecithin, the NAMPT recombinant protein can promote restoration of white matter after injury and strengthen post-injury neurologic function reestablishment. Results show that the NAMPT recombinant protein plays a long-term neuroprotective role in drugs treating cerebral stroke, traumatic brain injury and multiple sclerosis, and can be used as a neuroprotective drug to treat acute and chronic injury caused by brain stroke.
Owner:FUDAN UNIV

Jasminoidin or gardenia total iridoid glycoside liposome preparation

The invention discloses a jasminoidin or gardenia total iridoid glycoside liposome preparation which comprises liposome formed by phospholipid and cholesterol, and asminoidin or gardenia total iridoid glycoside wrapped and loaded in the liposome, wherein the weight ratio of phospholipid to cholesterol is (3:1)-(7:1), preferably 5:1; the weight ratio of asminoidin or gardenia total iridoid glycoside to phospholipid is (1:2)-(1:8), preferably 1:4; and the phospholipid is selected from lecithin, soya lecithin, yolk phospholipid or phosphatidylcholine, preferably soya lecithin or yolk phospholipid. The preparation provided by the invention has the advantages that the contact time of the asminoidin or gardenia total iridoid glycoside and mucosa is prolonged. The liposome preparation can be prepared into a spraying agent after being loaded into a nasal suction apparatus, and is applied in a nasal delivery mode, so that the distribution of the asminoidin or gardenia total iridoid glycoside in brain tissues is effectively improved. The invention also discloses the application of the liposome preparation in preparation of medicaments for treating hypoxic ischemic brain damage diseases.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Portable box for crania-cerebral perfusion cooling

ActiveCN104288896AImprove brain protectionAvoid reperfusion injuryMedical devicesTherapeutic coolingControl systemTemperature monitoring
The invention relates to a portable box for crania-cerebral perfusion cooling. The portable box comprises a control system (1), a constant temperature cooling device (2), a drive perfusion device (3), a power source (4), an operation panel (5) and external ports (6 and 7). The control system (1) controls flowing of perfusion liquid in the constant temperature cooling device (2) via the external ports (6 and 7) by controlling the drive perfusion device (3). A temperature monitoring component and a water level monitoring component are arranged in the constant temperature cooling device (2), the temperature monitoring component is used for monitoring a temperature signal of the perfusion liquid in the constant temperature cooling device (2) and monitoring an indoor temperature signal, and the water level monitoring component is used for monitoring the liquid level information of the perfusion liquid. The operation panel (5) can display the information of the temperate, the flow rate, the residue liquid amount and the like of the perfusion liquid in real time, a certain amount of crania-cerebral perfusion cooling liquid with the temperature being within the range of 0-4 DEG C is perfused to a brain local area at an appropriate speed, so that the temperature in the area reaches mild hypothermia as soon as possible, and thus the mild hypothermia therapy requirement for ischemic brain injury can be met.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Carbonic oxide inhalator

The invention discloses a carbonic oxide inhalator which comprises a control part, a measuring circuit part and a CO-air mixing device. The CO-air mixing device is provided with a CO inlet, an air inlet and a mixed gas outlet. The control part comprises a computer and a displayer. The measuring circuit part comprises a pressure sensor, a current amplifier, a filter and an A / D convertor, wherein the pressure sensor measures the gas pressure of input CO gas, air and mixed gas, current amplification and filtering are conducted on the gas pressure through the current amplifier and the filter respectively, then the gas pressure is converted into a digital signal through the A / D convertor and is input into the computer, and the computer analyzes data of the measuring circuit part and outputs a control command. The carbonic oxide inhalator is used for treating diseases such as pulmonary arterial hypertension, ARDS, respiratory failure caused by acute lung injury, hypoxic ischemic brain damage and shock.
Owner:史源
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products